跳至主要内容

Medicilon Ophthalmic Animal Models

 Medicilon Ophthalmic Animal Models

Dry eye, also known as dry eye disease (DED), dry eye syndrome, and keratoconjunctivitis sicca (KCS), is a multifactorial disease of the ocular surface. Dry eye is characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiologic roles.
Dry eyes affect a significant number of people, the cause of dry eye is multifactorial, in which ocular, anatomical and systemic factors play crucial roles. Prompt treatment significantly improves long-term quality of life, provides relief from dry eyes, and improves outcomes.

Model of Dry Eye Syndrome

Healthy rats were selected and given subcutaneous injections of scopolamine four times daily for 4 weeks and placed in dry room. Schemer‘s test and corneal conjunctiva stained with tiger red and fluorescein were performed before administration and on the 1st, 3rd, 5th, 7th, 14th, and 28th days after administration. The animals were euthanized on the 35th day after administration, and the conjunctiva, cornea, and lacrimal gland tissues were taken for light microscopic examination.

Testing parameters

  • Tear film break up time (BUT)
  • Schemer’s test
  • Slit Lamp exam: Corneal fluorescent staining test
  • Histopathology
Medicilon Ophthalmic Animal Models
Medicilon Ophthalmic Animal Models
Medicilon has established ocular diseases models, including the Conjunctival tissue proliferation and NV, Diabetic retinopathy (DR), Choroidal neovascularization (CNV) and subretinal fibrosis, Corneal neovascularization (Corneal NV), Retinal neovascularization, Acute ocular inflammation, and dry eye models. Learn More.

Schimer test results (tear secretion, mm)

Schimer test results (tear secretion, mm)​

Methods

After suctioning off the excess tear fluid from eyes, take 5 × 35 mm test paper with scale, fold one end back for 5 mm, gently put it into the middle and outer 1/3 of the inferior conjunctival sac of the testing eyes, take out the filter paper after 5 minutes and measure the wet length. Generally, 10-30 mm/ 5 min is normal. Less than 5 mm can be diagnosed as tear deficiency, 6-10 mm may be suspected of decreased secretion, and more than 10 mm is normal. If the filter paper is fully wet in less than 5 minutes, the time of full wetness will be recorded.

Tear film break-up time(s)

Tear film break-up time(s)​

Methods

Drop 1 µL of 10 g/L fluorescein sodium into the conjunctival sac and close the eyelid, observe under slit lamp microscope with the cobalt blue light. After three blink reflexes (BR), the time from the last BR to the appearance of the first dark spot in the cornea is defined as tear film break-up time.

Fluorescein staining

Fluorescein staining​

Methods

Positive results of fluorescence staining reflect corneal epithelial cell defects, the cornea is divided into four quadrants, 0 points for no staining, three grades for light, medium, and heavy staining, 1 point for less than five staining dots, 3 points for lumps or filaments staining, and 2 points between the above two, total 0-12 points.

Slit lamp examination (typical symptom I)

Slit lamp examination (typical symptom I)

Slit lamp examination (typical symptom ll)

Slit lamp examination (typical symptom II)

Slit lamp examination (typical symptom lll)

Slit lamp examination (typical symptom III)

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati